Progressing innovative development pipeline with 4 compounds targeting novel treatments for diabetic eye disease.
OASIS Phase IIIb 2 year follow up study confirms long term safety and efficacy of ocriplasmin - publication in Ophthalmology AAO Journal
- ThromboGenics progressing attractive portfolio of novel medicines for the treatment of diabetic eye disease: 4 compounds targeting novel treatments for diabetic retinopathy (DR) - non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), in the presence or absence of diabetic macular edema (DME)
- ThromboGenics is conducting a Phase IIa clinical study (CIRCLE) evaluating THR-409 (ocriplasmin) to induce a complete posterior vitreous detachment (PVD), to prevent patients with non-proliferative diabetic retinopathy (NPDR) from progressing to proliferative diabetic retinopathy (PDR), a serious sight threatening condition
- ThromboGenics signed a global and exclusive license agreement with Galapagos to develop and commercialize integrin antagonists for the treatment of diabetic eye disease. The Company has started to explore the potential of these compounds, including THR-687, for the treatment of NPDR and PDR
- ThromboGenics is developing THR-317, an anti-PlGF inhibitor, for the treatment of DME which is on track to enter the clinic by end of 2016.
- Oncurious has started a Phase I/IIa study evaluating TB-403 in children with medulloblastoma in May
- In H1 2016, ThromboGenics reported overall revenues of €4.0 million from JETREA®, including €1.4 million in royalty income from its partner Alcon (Novartis)
- Positive data of OASIS 2 year Phase IIIb study evaluating JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole (n=220) has been published in Ophthalmology, Journal of the American Academy of Ophthalmology.
- Cash and investments were €91.5 million as of the end of June 2016. This compares to €101.4 million on December 31, 2015.
Leuven, Belgium – 25 August 2016 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, today issues a business update for the six month period ending 30 June, 2016.
ThromboGenics is developing novel medicines for diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edema (DME).
ThromboGenics is developing an attractive pipeline of disease modifying drug candidates for diabetic eye disease. The pipeline consists of THR-409, THR-317, both from the Company’s in-house research, as well as THR-149 which resulted from a research collaboration with Bicycle Therapeutics, and THR-687, which was in-licensed from Galapagos NV in March 2016.
These products all have different modes of action and will allow the Company to address the four key segments of the rapidly growing diabetic eye disease market:
- Non-proliferative DR
- Proliferative DR
- Non-proliferative DR with DME
- Proliferative DR with DME
Dr. Patrik De Haes, ThromboGenics’ CEO,said: “ThromboGenics is progressing its exciting drug development pipeline of potential new disease modifying medicines for the treatment of diabetic eye disease. Diabetic Retinopathy and Diabetic Macular Edema are significant indications where there are clear unmet medical needs and a strong demand for improved or add-on treatment options. With our innovative pipeline, we believe we can address all key segments of the diabetic eye disease market and generate attractive returns for our shareholders.”